Led · Series C · Jun 2026

Flare Therapeutics is a clinical-stage biotech headquartered in Cambridge, Mass., that focuses exclusively on drugging transcription factors using an integrated discovery platform to identify ligands to previously undrugged proteins. The company has prioritized FX-111, a first-in-class degrader targeting ARON for prostate cancer, which received IND clearance and is expected to enter clinical development in Q3 2026. FlareTx is also advancing an ARON RIPTAC program through preclinical development to complement FX-111 and expand its ability to address AR-driven prostate cancer. Separately, FX-909, an oral PPARG inhibitor targeting luminal lineage biology in urothelial cancer, is in a Phase 1B dose expansion and the company intends to progress it via an external partnership. The recent $85M Series C provides capital to advance these programs, support working capital and general corporate purposes. The company appointed Anna Protopapas as CEO concurrent with the financing to guide its next phase of clinical and corporate development.

Participated · Series C · Apr 2026

Terremoto Biosciences is a clinical-stage biotech company focused on designing highly selective, potent small-molecule AKT1 inhibitors. Its lead oncology program, TER-2013, is in Phase 1 clinical development for solid tumors harboring PIK3CA, AKT, or PTEN alterations. The company is also advancing TER-4480 for hereditary hemorrhagic telangiectasia, with clinical entry expected later this year. Terremoto emphasizes AKT1 selectivity to maximize efficacy while minimizing toxicities associated with AKT2 or PI3Kα inhibition. It is privately held and supported by investors including OrbiMed, Third Rock Ventures, Novo Holdings, Cormorant Asset Management, RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines. Terremoto is based in South San Francisco and San Diego.

Led · Series A · Dec 2025

Syremis Therapeutics is advancing a neuropsychiatric pipeline grounded in clinically validated mechanisms, aiming to create best-in-class treatments for schizophrenia, major depressive disorder, bipolar depression and other psychiatric conditions. Its lead asset, ST-905, is a potent dual M1/M4 muscarinic receptor agonist now in Phase 1 trials and designed for once-daily oral dosing with the potential for a long-acting injectable formulation. A second program, ST-901, is a next-generation NMDA antagonist in IND-enabling studies and slated to enter Phase 1 next year to address depressive disorders. Both candidates originated at Clexio Biosciences before being spun out to Syremis. The company highlights the vast unmet need in schizophrenia, which affects more than 20 million people globally, and cites limitations in efficacy and tolerability of current therapies as its market entry point. Syremis is led by a seasoned team including co-founders Elisabeth Kogan (CEO), Elena Kagan (CDO), and Menashe Levy (CTO), with board members drawn from Dexcel Pharma, Third Rock Ventures, Bain Capital Life Sciences and other industry leaders. Its $165 million Series A financing provides the capital to advance both programs through clinical proof of concept. No commercial revenues or patient enrollment figures have been disclosed to date.

Led · Series A · Nov 2025

Azalea Therapeutics engineers Enveloped Delivery Vehicles (EDVs) that transport transient CRISPR-Cas9 cargo directly to specific cell types for precise, in-vivo genome editing. Its lead program uses CD19-targeting EDVs and T-cell-tropic AAVs to insert a CAR construct at a defined genomic locus, producing physiologic and sustained CAR-T activity against B-cell malignancies and autoimmune diseases. Additional pipelines include a BCMA-targeted in-vivo CAR-T for multiple myeloma and an undisclosed solid-tumor program, with plans to extend the platform to other cell types. By eliminating ex-vivo manufacturing, Azalea aims to deliver potent, durable and safe therapies conveniently inside patients. Co-founded by Nobel laureate Jennifer Doudna, along with Michael Fischbach, Justin Eyquem and Jenny Hamilton (CEO), the company brings deep expertise in genome engineering, synthetic biology and cell therapy. To date, Azalea has secured $82 million in seed and Series A financing to advance its lead programs through IND-enabling studies and into early clinical trials.

Participated · Series B · Jul 2025

ARTBIO develops alpha radioligand therapies (ARTs) and is advancing multiple pipeline programs with a lead program, AB001, currently in first-in-human trials. The company’s AlphaDirect™ proprietary generator technology enables flexible, distributed production of clinical-grade lead-212 to support dosing and a resilient supply chain. ARTBIO plans to expand its manufacturing network and supply-chain infrastructure to support global clinical trials and eventual commercialization. Proceeds from the recent financing will accelerate AB001 through Phase II and move additional undisclosed programs toward IND readiness. The company highlights a scientific legacy tied to the University of Oslo and Norway’s Radium Hospital and operates from Cambridge, Massachusetts and Oslo, Norway. ARTBIO is a clinical-stage radiopharmaceutical company based in Cambridge, MA and Basel, Switzerland, focused on developing alpha radioligand therapies for cancer. Led by CEO Emanuele Ostuni, Ph.D., the company selects Pb212 as its chosen alpha precursor and pairs it with tumor-specific targets to create its alpha radioligand therapies (ARTs). Its proprietary AlphaDirect™ Pb212 isolation technology enables a distributed manufacturing approach for production and delivery of ARTs. ARTBIO is advancing three pipeline programs with lead candidate AB001 currently in first-in-human trials for prostate cancer. The company intends to use the Series A proceeds to solidify AlphaDirect™, expand its distributed manufacturing network, advance AB001 in the clinic, and further its pipeline. Concurrent with the Series A closing it appointed Philippe Dasse as Chief Technical Officer and Daniel Rossetto as Head and Senior Vice President of Supply Chain and External Manufacturing.